It is well recognized that nitric oxide (NO) is involved in tumor progression, including melanoma. Measurement of proliferative and metastatic capacity by MTS and Matrigel invasion assays, respectively, was done and showed that NO-treated melanoma cells exhibited a higher capacity compared with control, especially metastatic 
Introduction
Nitric oxide (NO) produced during the conversion of L-arginine to L-citrulline by NO synthase (NOS) is an important bioactive agent and signaling molecule required for many physiologic functions (1, 2) . Recently, studies of NO function have focused on its role in tumor. A majority of human and experimental tumors are stimulated by NO, which contributes to tumor growth and metastasis by promoting migratory, invasive, and angiogenic properties of tumor cells (3, 4) . One such example is that scavenging of endogenous NO resulted in inhibition of melanoma cell growth, which was restored with a NO donor (5) .
Melanoma, arising from melanocyte, is a highly metastatic tumor and the incidence has ranked fifth and sixth among the most common cancer afflicting men and women. Although a strong relationship is reported between UV radiation and melanoma with acute sun exposure being implicated in melanomagenesis (6) , the mechanisms controlling progression are poorly understood. An increasing number of publications support the notion that UV radiation stimulates the production of NO in human keratinocyte (7 -9) , causing a series of secondary downstream changes and release of cytokines and other molecules that are of critical importance in the maintenance of normal melanocyte homeostasis and in the modulation of melanocyte proliferation, dendricity, and melanin synthesis (10 -12) . Therefore, NO generated by the keratinocyte is postulated as being involved in melanomagenesis and progression.
Apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) possesses both DNA repair and redox regulatory activity. It regulates the DNA binding of a number of transcription factors, including activator protein-1 (AP-1), nuclear factor-nB (NF-nB), Pax-5, and Pax-8 in both redox-dependent and redox-independent manners (13 -16) . APE/Ref-1 is essential for cell survival and proliferation, as mice lacking a functional APE/Ref-1 gene die during embryonic development (17) . Also, antisense APE/Ref-1 overexpression induces a striking increase in cell sensitivity to oxidative stress (18) . Thus, APE/Ref-1 has attracted attention on account of its multiple roles, especially in tumors. Several studies show that APE/ Ref-1 is very sensitive to the redox disequilibrium that often occurs in tumor cells (19) . Additionally, melanoma cells have diminished antioxidant potential compared with normal melanocytes, which leads to an accumulation of reactive oxygen species through increased production as well as impaired clearance in different stages of melanoma development (20) . Our previous data also showed a role of APE/Ref-1 in melanoma transformation and development of drug resistance (21) . Based on this broad spectrum of findings, it has become increasingly cogent to investigate the role of APE/Ref-1 as a pivotal therapeutic target in melanoma.
Resveratrol (3,5,4 ¶-trihydroxystilbene) is a naturally occurring compound present in grapes and in red wine, which has been suggested as a potential chemopreventive and antitumor agent based on its striking inhibitory effects on diverse cellular events associated with tumor initiation, promotion, and progression (22) . Thus far, the underlying molecular basis for these effects has been elusive, although its antioxidant activity as a reactive oxygen species scavenger clearly is of significance (23) . In addition, we have shown that resveratrol is an APE/Ref-1 inhibitor in a previous study (24) .
In the current investigation, we present evidence that NO-induced APE/Ref-1 is crucial in initiating a positive functional feedback loop in melanoma cells with involvement of AP-1/JunD, MMP-1, Bcl-2, and iNOS. Resveratrol directed against APE/Ref-1 interrupted this loop, suggesting that it might be an effective inhibitor of progression or enhancer of therapeutic agent activity that is blocked by the high NO level.
Materials and Methods

Cell Culture
The metastatic melanoma cell line Lu1205 was cultured in L15/MCDB medium with 5% fetal bovine serum, 5% newborn calf serum, 100 units/mL penicillin, and 0.1 mg/mL streptomycin. The primary melanoma cell line (Wm3211) was cultured in RPMI 1640 with 5% fetal bovine serum, 5% calf serum, 100 units/mL penicillin, 0.1 mg/mL streptomycin, and 0.01 mg/mL insulin. These cells were generous gifts from Dr. Meenhard Herlyn (The Wistar Institute, Philadelphia, PA). The passage number for the cell strains used in these experiments was V8. Cells were treated at 70% confluence with fresh medium and drug was added simultaneously.
Reagents and Antibodies
The NO donor DETA/NO, (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino] diazen-1-ium-1,2-diolate, was from Alexis Biochemicals. It was dissolved in PBS and used at a concentration of 100 Amol/L. In medium (pH 7.4), DETA/ NO spontaneously releases NO with a half-life of f20 h at 37jC. Resveratrol was purchased from Sigma Life Sciences, dissolved in DMSO, and used at a concentration of 50 Amol/L.
The following primary antibodies were used for Western blot analysis: APE/Ref-1 was from Novus Biologicals; AP-1/JunD, MMP-1, Bcl-2, and iNOS were from Santa Cruz Biotechnology; and a-Tubulin was from Sigma Life Sciences. The following secondary antibodies were used: horseradish peroxidase -conjugated anti-mouse antibody and anti-rabbit antibody were from Santa Cruz Biotechnology.
Cell Proliferation Assay The MTS assay (CellTiter 96 Aqueous Nonradioactive Cell Proliferation Assay, Promega) was used for measurement of cell proliferation. Briefly, cells were seeded into 96-well plates at a density of 1.5 Â 10 4 per well, incubated overnight, and exposed to DETA/NO. At the indicated time, 20 AL MTS reagent (10 mg/mL in PBS) were added to each well and allowed to react for 3 h at 37jC. Substrate cleavage was monitored by using a microplate reader (BioRad) at 490-nm wavelength and analyzed by using related software. The percentage was defined as [(experimental OD À blank OD ) / (control OD À blank OD )] Â 100%, where the blank OD was determined in wells containing medium and MTS only.
Invasion Assay
The invasiveness of melanoma cell was assessed based on the invasion of cells through Matrigel-coated membrane (pore size, 8.0 Am). According to the manufacturer's instructions, two groups of cells (control and DETA/ NO -treated cells) were collected and reconstituted in serum-free medium at a final concentration of 4 Â 10 5 cells/mL. Serum-free medium (750 AL) was added to each well and 500 AL of prepared cells were added to the upper Matrigel-coated insert (BD Biosciences). After an incubation of 72 h, cells were fixed with ice-cold methanol and then stained with hematoxylin. Subsequently, membranes were cut off, mounted in mounting medium on slides, and visualized microscopically (Olympus Optical Co. Ltd.). The invading cells on each of triplicate membranes were counted and averaged for 10 randomized fields at Â400 magnification, and a photograph was taken at Â100 magnification.
Cell Protein Extraction and Western Blot Analysis After treatment with DETA/NO or resveratrol for specified times, melanoma cells were collected and lysed as described previously (21) . By using a detergentcompatible protein assay kit (Bio-Rad), the protein concentration was precisely measured thrice. Equal amounts of the soluble protein were denatured, subjected to SDS-PAGE, and transferred to nitrocellulose membranes. The specific protein was then detected by the antibodies [anti-APE/Ref-1 (1:3,500), anti-iNOS, anti -Bcl-2 and anti -MMP-1 (1:100), anti -AP-1/JunD and anti -a-Tubulin (1:1,000)] followed by a chemiluminescence detection reagent. Measurement of signal intensity on membranes was done using an imaging densitometer with Multi-Analyst software (Bio-Rad). For statistical analysis, all data were expressed as fold change of the control based on the calculation as the density values of the specific protein bands/ a-Tubulin density values. All figures showing quantitative analysis include data from three independent experiments.
Quantitative Real-time ReverseTranscription-PCR To confirm the RNA expression level, total RNA was isolated by using TRIzol according to the manufacturer's protocol (Invitrogen, Inc.). RNA concentration was determined by using spectrophotometer. Equal amounts of Electrophoretic Mobility Shift Assay The AP-1 DNA-binding activity was determined by Gel Shift Assay Systems (Promega) with optimizations. In brief, nuclear extracts from Lu1205 melanoma cells, with or without DETA/NO treatment, were incubated in a final volume of 10 AL containing 2 AL of Gel Shift binding buffer (five times) and 1 AL of 32 P-labeled AP-1 consensus oligonucleotides. The specificity of binding was determined by competition with preincubation with a 50-fold excess of unlabeled oligonucleotide probes for 20 min before the addition of hot probes. The reaction mixture was separated on 5% nondenaturing polyacrylamide gels. Through autoradiography, the shift bands were visualized.
Statistical Analysis Data are presented as the mean F SD from three independent experiments. Student's t test was used to compare two groups, with a P value of <0.05 considered statistically significant. All tests were two sided.
Results
DETA/NOPotentiates the Proliferative and Metastatic Capacities of Melanoma Cells
To investigate the effect of NO on proliferative and metastatic capacities of melanoma cells, the MTS and invasion assays were used. Cell viability was measured on days 1, 2, 3, and 4. After a 24-hour exposure to DETA/NO, Lu1205 cell viability initially showed a slight decrease followed by an evident increase. By the 4th day, the viability of DETA/NOtreated Lu1205 cells was f1.5 times greater compared with control cells. Primary Wm3211 cells were stimulated, although less than that of metastatic Lu1205 cells (Fig. 1A) .
Matrigel invasion assay confirmed that the invasiveness of treated cells increased, particularly the metastatic Lu1205 melanoma cells (Fig. 1B) . The average number of treated Lu1205 cells invading the underside of the membrane was f5.5 times higher than that of control cells. Following DETA/NO treatment, primary Wm3211 cells also showed an elevated but less invasive capacity, about a 2-fold increase.
NO Fig. 2A ). The elevation was not so significant in Wm3211 cells at a 1.3-and 1.9-fold increase, respectively (Fig. 2B) . Also, APE/Ref-1 protein level increased in metastatic A375, c81-46A, and c81-61 melanoma cells treated with DETA/ NO, which were all higher than Wm3211 (data not shown). 
Role of AP-1/JunD in NO-Stimulated Melanoma Cells
To study the possible role of AP-1/JunD for involvement in NO-stimulated melanoma cells, we first treated Lu1205 cells with DETA/NO and subjected the nuclear extracts to electrophoretic mobility shift assay. Figure 4A (lane 1) showed that specific AP-1 DNA binding was competed by unlabeled AP-1 consensus oligonucleotide (Â50). The binding activity of AP-1 was enhanced by NO stress, especially after 2-hour (lane 4) and 12-hour (lane 6) treatments, which coincided well with the two peaks of APE/Ref-1 induction by NO stress (Fig. 2A) . Next, we knocked down AP-1/JunD with siRNA (Fig. 4B, a) . 
and iNOS
We studied molecule expression changes after resveratrol and DETA/NO treatment in three groups of melanoma cells (control cells, cells pretreated with resveratrol for 24 hours followed by a 24-hour incubation of fresh medium without resveratrol, and cells pretreated with resveratrol for 24 hours followed by a 24-hour incubation of DETA/NO with fresh medium). As shown in capacity between control and DETA/ NO -treated cells. Representative pictures were taken from the underside of the membrane at Â100 magnification. The level of control was set at a value of 1. Data are fold change of control. *, P < 0.05; **, P < 0.01 versus control. Columns , mean of three independent experiments; bars , SD.
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molecules either in Lu1205 (Fig. 5A) or Wm3211 (Fig. 5B ) melanoma cells.
Discussion
The present study was oriented to understanding the role of APE/Ref-1 in mediating the effect of NO in melanoma progression. The proposed mechanistic schema resulting from our studies is summarized in Fig. 6 AP-1 consists of a group of structurally and functionally related members of the Jun and Fos protein families. JunD, a broadly expressed member of the Jun family, was reported to protect cells from senescence or apoptotic responses to stress stimuli and lead to a release from cell contact inhibition (26, 27) . Our data also confirmed that increased AP-1/JunD level was accompanied by elevated proliferative capacity in DETA/NO -treated melanoma cells. Additionally, some attempts to correlate NO with AP-1 in other cellular system uncovered a positive relationship between them: NO increased AP-1 activity (28, 29) and the inhibition of AP-1 led to the inhibition of NO formation as well (30) . In melanoma cells, AP-1/JunD was activated and its DNA-binding activity was enhanced with the trend nearly paralleling that of APE/Ref Bcl-2, an important downstream molecule regulated by NF-nB, is closely tied to apoptosis. Exogenous NO has been reported to prevent apoptosis by inhibiting the drop in Bcl-2 levels (36) . Similarly, the protection of keratinocytes and endothelial cells from UV-induced apoptosis was mediated through endogenous NO-stimulated increase in Bcl-2 expression (37) , implying that NO affected the expression of Bcl-2. Results from our study showed that Bcl (38) . Hence, the stimulation of 
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Bcl-2 by NO stress in melanoma cells was likely via APE/ Ref-1 pathway based on its regulation of NF-nB.
Recent findings indicated that an increase in iNOS expression was associated with various tumors, including melanoma (39 -41) , and the up-regulation of this enzyme has been well correlated with tumor progression and poor survival. Remarkable expression has been found in malignant melanomas, especially in the invasive phase (42, 43) ; in particular, constitutive iNOS leads to intracellular NO production that is directly responsible for supporting melanoma growth (5), which further support the notion that iNOS and the release of NO all play important roles in the progression of metastatic human melanoma. In contrast, transfection with the iNOS gene in murine melanoma cells suppressed tumorigenicity and abrogates metastasis (44) . This inconsistency might be explained by the distinct difference among species.
Furthermore, the promoter of the iNOS gene contains several homologous consensus sequences as binding sites for transcription factors, which are believed to be essential for iNOS gene transcription, especially AP-1 (45) . In some cases, the inhibition of iNOS expression was found only through the suppression of AP-1 (46) . Consistently, our data showed that knockdown of AP-1/JunD prevented the induction of iNOS. Moreover, as we depleted APE/Ref-1 by siRNA, the expression levels of iNOS and AP-1/JunD always paralleled that of APE/Ref-1. Therefore, we proposed that the regulation of iNOS by AP-1 mediated by APE/Ref-1 is involved in modulating the redox balance within the melanoma cell based on our data and related literature (47) .
Resveratrol inhibits growth, induces apoptosis, suppresses angiogenesis, and blocks the reactive oxygen species -potentiated invasion of tumor cells (48, 49) . In In summary, the present study shows that APE/Ref-1 induced by NO stress initiates a functional feedback loop contributing to the proliferation and metastatic capacity of melanoma cells, which can be interrupted by resveratrol. This compound may be useful in combination with other agents whose actions are blocked by up-regulation of these downstream molecules. 
